During the past decade, Hospital Universitario HM Montepríncipe conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 1 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario HM Montepríncipe" #1 sponsor was "Pfizer" with 4 trials, followed by "PharmaMar" with 3 trials sponsored, "BioNTech SE" with 2 trials sponsored, "Bama GeVe, S.L.U." with 1 trials sponsored and "Biomendi S.A.U." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario HM Montepríncipe" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "Apices Soluciones S.L." with 2 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Medivation, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario HM Montepríncipe" are "COVID-19" (2 trials), "COVID-19 Infection" (2 trials), "Pneumococcal Disease" (2 trials), "Venous Thromboembolism" (2 trials) and "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Hospital Universitario HM Montepríncipe" in a lesser frequency.

Most popular intervention types in "Hospital Universitario HM Montepríncipe" are "Drug" (10 trials), "Biological" (4 trials), "Other" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "13-valent pneumococcal conjugate vaccine" (2 trials), "20-valent pneumococcal conjugate vaccine" (2 trials), "Enzalutamide" (2 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario HM Montepríncipe" are 14 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Universitario HM Montepríncipe". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Hospital Universitario HM Montepríncipe, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario HM Montepríncipe, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".